The Medicines and Healthcare Products Regulatory Agency (MHRA) has reported the outcome of its consultation on the application of Analytical Quality by Design (AQbD) principles to pharmacopoeial standards for medicines.
MHRA had investigated how Analytical Quality by Design (AQbD) principles may be applied to pharmacopoeial standards, in order to ensure best principles are used at every stage of medicine regulation.
Following the consultation, MHRA said:
“The following four strategic objectives have been identified:
- Develop and publish new standards and guidance
- Further explore the application of AQbD concepts
- Build capability across the Agency
- Engage and collaborate with stakeholders”
Read the MHRA press release for more information.